Overview

TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.
Phase:
Phase 2
Details
Lead Sponsor:
Trigemina, Inc
Treatments:
Oxytocin